Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment

Abstract

Acantholytic dyskeratotic acanthoma (ADA) is a solitary small papule that is pathologically characterized by dyskeratosis with acantholytic acanthosis (1). Vemulafenib is a specific inhibitor of BRAF protein kinase with V600E mutation and is administered to treat metastatic melanoma. Various skin adverse events associated with vemurafenib, including acantholysis and flare up of Darier's disease, have been reported (2, 3). Here we report a case of ADA that developed during vemulafenib treatment for metastatic melanoma. Our case suggests a possibility that vemurafenib may affect epidermal structures which induces acantholysis and dyskeratosis.

This article is protected by copyright. All rights reserved.

http://ift.tt/2oZY8vg